

CanREValue

Value-based decisions from Real World Evidence

Winter 2022 Newsletter

Issue 13 | Winter 2022

Study Objectives:

Objective 1: (ongoing)

- ❖ Develop comprehensive understanding of the current state of RWE nationally & internationally
- ❖ Keep current on emerging/new information related to RWE in Canada and beyond

Objective 2: (established & ongoing)

- ❖ Establish formal national working groups dedicated to policy and methodological application of RWE, and collaboratively & iteratively develop a working framework

Objective 3: (ongoing)

- ❖ Validate the developed framework through the completion of a multi-province RWE project

Objective 4: (ongoing)

- ❖ Employ knowledge translation strategies to establish and integrate the final RWE framework

2021 CANREVALUE VIRTUAL ANNUAL MEETING UPDATE

Happy New Year! Welcome to the latest edition of the CanREValue Newsletter.

This past October we successfully hosted our second virtual Annual Meeting for members of the CanREValue Collaboration. The meeting brought together members to review the progress of the CanREValue Collaboration and ensure agreement regarding the preliminary Framework. Additionally, each Working Group took the opportunity to provide members with an update on their progress and current stage in the demonstration project.

During the Annual Meeting, two breakout sessions were conducted to explore (1) how RWE can support decision-making in ways other than to assess the generalizability of RCT finding in the real world and when it may not be a solution to resolve uncertainty for decision-making and (2) the existing gaps and barriers to the implementation of time-limited recommendations and ways to further leverage components of the CanREValue Collaboration Framework to support time-limited recommendations.

Please email us at CanREValue@cc-arcc.ca if you have any questions or need additional information

CANREVALUE PATIENT ENGAGEMENT – ENGAGEMENT WORKING GROUP

On October 21st, 2021 the Engagement Working Group brought together a group of patient groups and individual patient representatives for a second patient engagement consultation following the first session

held on August 24th, 2021. The purpose of the second patient engagement consultation was to hear additional feedback on issues relating to the [Policy WG Interim Report](#) not addressed during the first consultation and hear feedback on changes made to the Interim Report suggested during the first consultation. A summary of the second consultation was shared with the participating members in December, 2021. Thank you again to those CanREValue Collaboration members who participated in the Patient Engagement Consultation and provided feedback on the discussion.

Contact CanREValue@cc-arcc.ca should you have any questions regarding the Patient Engagement sessions or the Engagement Working Group.

PARTNER INFORMATION - 2022 ARCC CONFERENCE – CALL FOR ABSTRACTS:

The Canadian Centre for Applied Research in Cancer Control (ARCC) is accepting online abstract submissions for oral and poster presentations to be presented at their tenth annual conference held virtually from May 16-17, 2022. The ARCC Conference is Canada's only applied cancer control research conference, bringing together policy and decision makers, researchers, clinicians, trainees, and other stakeholders to share work in the areas of health economics, services, policy, and ethics as it relates to cancer control in Canada. CanREValue will be showcasing recent work at #ARCC2022 – we hope to “see” you there!

Abstracts are due Friday, January 28th, 2022. For more information regarding abstract submission guidelines please follow the [link](#) or email Rebecca Mercer at rebecca.mercer@ontariohealth.ca.

WORKING GROUP UPDATES AND NEXT STEPS:

| Working Group | Updates & Next Steps |
|-----------------------------|--|
| Planning and Drug Selection | <p>Updates:</p> <ul style="list-style-type: none">• Second MCDA Soft Launch held on November 22nd, 2021. <p>Next Steps:</p> <ul style="list-style-type: none">• Continue assessing the MCDA rating tool. The next soft launch will take place on February 23rd, 2022.• Submit MCDA commentary article for publication (currently under final revision) |
| Data | <p>Updates:</p> <ul style="list-style-type: none">• Presented abstracts on the real-world effectiveness and cost-effectiveness from ON presented at CADTH2021 and CCRC 2021• Submitted manuscripts on the real-world effectiveness and cost-effectiveness from ON• Held 2 interprovincial meetings to discuss analytical issues in each province since summer 2021.• <i>Developing a pan-Canadian companion access guide and province-specific compliance recommendations for CIHI's pan-Canadian Oncology Drug Data Minimum Data Set</i> proposal submitted to the Canadian Cancer Society - Data Transformation Grant competition <p>Next Steps:</p> <ul style="list-style-type: none">• Continue with real-world analysis in 9 provinces |
| Methods | <p>Next Steps:</p> <ul style="list-style-type: none">• Consult and discuss appropriate methodology for next identified outcome measure• Continue support of Data WG on 9 province analysis |

Reassessment and Uptake

Updates:

- Exploring the opportunities to operationalize Step 4 through a demonstration project.
- Manuscript on the Mock Reassessment exercise with the WG members have been accepted by Current Oncology.

Next Steps:

- Continue working with WG members and relevant stakeholders to further operationalize Step 4 through a demonstration project.

Engagement

Updates:

- Held a second patient engagement consultation on October 21st, 2021 with 23 patient representatives.
- Drafted and circulated a summary document highlighting key patient feedback received on key policy and data access issues (Policy WG Interim Report and Data WG Interim Report).


Next Steps:

- Planning an Engagement WG teleconference on February 10, 2022
- Drafting a manuscript of the patient engagement experience

MEMBER SPOTLIGHT – REBECCA MERCER, MANAGER, ARCC NETWORK

Q: What is your educational background and how did it lead to an interest in RWE?

I completed a BSc in Biomedical Science at the University of Guelph, following which I participated in mixed-methods research surrounding evidence based care in child and youth work in Ontario. This exposure to research led me back to school, where I completed my PhD in Medical Sciences-Medical Genetics at the University of Alberta. During my PhD, I worked heavily with an academic research now known as Obesity Canada (previously the Canadian Obesity Network), leading their Student and New Professional group and participating heavily in knowledge translation (KT) activities. This is where I found my real research passion in the KT space, which ultimately led me towards the Canadian Centre for Applied Research in Cancer Control (ARCC), where I have been acting as a program manager since late 2013. In this role, I have an unparalleled opportunity to be involved with and engage in research in the applied cancer space across Canada. I am proud to have helped develop ARCC's key research area in real-world evidence, including by directly supporting the CanREValue Collaboration as a core team member.



Q: What aspect of the CanREValue project are you the most excited to work on?

For me, the most exciting part of CanREValue is being able to be so directly connected to the relevant stakeholders who will use the CanREValue framework, from patients to decision makers. Seeing such strong support for our work from such a broad range of passionate individuals is motivating every day.

Q: What has been the most interesting aspect of this project for you so far? Across my career, I have not had as much opportunity to engage patients in research as I would have liked and am keen to improve on this. With patient engagement being important to the CanREValue Collaboration, I have had some opportunity to be involved, through maintaining our web mailing list, and assisting with the Engagement WG.

While we have hit some speedbumps along the way as we learn, the dedication and openness of our patient members is inspiring, and really cements the need for patient inclusion in my mind.

Q: How can we reach you?

You can email me at rebecca.mercer@ontariohealth.ca. You can find out more about ARCC at <https://cc-arcc.ca/>, and our 2022 Conference at <https://cc-arcc.ca/arcc-conference-2022/> - hope to see you there!

Recent Publications/Presentations:**Presentations:**

Dai, Wei Fang, Jaclyn Beca, Chenthila Nagamuthu, Ning Liu, Craig Earle, Maureen Trudeau, Claire de Oliveira, and Kelvin Chan. "Real-world cost-effectiveness of pertuzumab (P) with trastuzumab in patients with metastatic breast cancer: population-based patient-level retrospective cohort study conducted by the CanREValue Collaboration." (CCRC 2021).

Dai, Wei Fang, Jaclyn Beca, Chenthila Nagamuthu, Ning Liu, Craig Earle, Maureen Trudeau, Claire de Oliveira, and Kelvin Chan. "Real-world effectiveness of pertuzumab with trastuzumab in patients with metastatic breast cancer: population-based patient-level retrospective cohort study conducted by the CanREValue Collaboration." (CCRC 2021).

Dai, Wei Fang, Jaclyn Beca, Chenthila Nagamuthu, Ning Liu, Claire de Oliveira, Craig Earle, Maureen Trudeau, and Kelvin Chan. "Real-world comparative effectiveness of pertuzumab with trastuzumab and chemo in patients with metastatic breast cancer: A population-based patient-level retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration." (CADTH 2021).

Manuscripts:

Dai, W.F., Arciero, V., Craig, E., Fraser, B., Arias, J., Boehm, D., Bosnic N., Caetano, P., Chambers, C., Jones, B., Lungu, E., Mitera, G., Potashnik, T., Reiman, A., Ritcher, R., Beca, J.M., Denburg, A., Mercer, R.E., Parmar, A., Tadrous, M., Takhar, P., & Chan, K. K.W., on behalf of the CanREValue Collaboration Reassessment and Uptake Working Group (2021). Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group. *Current Oncology*, 28(5), 4174-4183.
Link: <https://www.mdpi.com/1718-7729/28/5/354>

Dai, W.F., Craig, E., Fraser, B., Chambers, A., Mai, H., Brown, M. B., Craig C.E, Evans, W.K., Geirnaert, M., Taylor, M., Trudeau, M., Sperber, D., Beca, J.M, Denburg, A., Mercer, R.E., Parmar, A., Tadrous, M., Takhar, P., Kelvin, & K.K.W., on behalf of the CanREValue Collaboration. (2021). Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise. *Current Oncology*, 28(6), 4645-4654.
Link: <https://www.mdpi.com/1718-7729/28/6/392>

Raphael, M.J., Raskin, W., Habbous, S., Tai, X., Beca, J., Dai, W.F., Arias, J., Forbes, L., Gavura, S., Biagi, J.J., Earle, C.C. & Chan, K.K.W (2021). The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. *JAMA network open*, 4(11), e2133388-e2133388.
Link: <https://jamanetwork.com/journals/jamanetworkopen/article-abstract/2786135>

